Formulation of a dry powder influenza vaccine for nasal delivery

AAPS PharmSciTech

Volumn 7, Issue 1, 2006, Pages

  Garmise, Robert J ^a   Mar, Kevin ^b   Crowder, Timothy M ^c,d   Hwang, C Robin ^b   Ferriter, Matthew ^b   Huang, Juan ^b   Mikszta, John A ^b   Sullivan, Vincent J ^b   Hickey, Anthony J ^a,c  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b Becton Dickinson Technologies   (United States)

^c NORTH CAROLINA STATE UNIVERSITY   (United States)

^d Oriel Therapeutics Inc   (United States)

Author keywords

Dry powder; Influenza vaccine; Intranasal delivery; Lyophilization; Mucoadhesive

Indexed keywords

CHITOSAN; INFLUENZA VACCINE; LACTOSE; TREHALOSE;

ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRY POWDER; FLOW RATE; FREEZE DRYING; PARTICLE SIZE; PHYSICAL CHEMISTRY;

EID: 33645018003     PISSN: 15309932     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt070119     Document Type: Article

References (31)

1. WHO. Influenza. WHO Fact Sheet, No 211. Geneva, Switzerland: World Health Organization; 2003.
2. Nichol KL, Mendelman PM, Mallon KP, et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in healthy,working adults: a randomized controlled trial. JAMA. 1999;282: 137-144.
3. Dyer O. Factory's loss of licence halves supply of flu vaccine to US. BMJ. 2004;329:876.
4. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today. 2002;7:1184-1189.
5. Groneberg DA, Witt C, Wagner U, Chung KF, Fischer A. Fundamentals of pulmonary drug delivery. Respir Med. 2003;97:382-387.
6. Roth Y, Chapnik JS, Cole P. Feasibility of aerosol vaccination in humans. Ann Otol Rhinol Laryngol. 2003; 112:264-270.
7. Gonda I. The ascent of pulmonary drug delivery. J Pharm Sci. 2000;89:940-945.
8. Singh M, Briones M, O'Hagan DT. A novel bioadhesive intranasal delivery system for inactivated influenza vaccines. J Control Release. 2001;70:267-276.
9. Muszkat M, Friedman G, Schein MH, et al. Local SIgA response following administration of a novel intranasal inactivated influenza virus vaccine in community residing elderly. Vaccine. 2000;18: 1696-1699.
10. Hirabayashi Y, Kurata H, Funato H, et al. Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine. 1990;8:243-248.
11. Russell MW, Moldoveanu Z, White PL, Sibert GJ, Mestecky J, Michalek SM. Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the Cholera toxin B subunit. Infect Immun. 1996;64:1272-1283.
12. Bergquist C, Johansson EL, Lagergard T, Holmgren J, Rudin A. Intranasal vaccination of humans with recombinant cholera toxin B subunit induces systemic and local antibody responses in the upper respiratory tract and the vagina. Infect Immun. 1997;65: 2676-2684.
13. Smith DJ, Bot S, Dellamary L, Bot A. Evaluation of novel aerosol formulations designed for mucosal vaccination against influenza virus. Vaccine. 2003;21:2805-2812.
14. Anderson J, Fishbourne E, Corteyn A, Donaldson AI. Protection of cattle against rinderpest by intranasal immunisation with a dry powder tissue culture vaccine. Vaccine. 2000;19:840-843.
15. LiCalsi C, Christensen T, Bennett JV, Phillips E, Witham C. Dry powder inhalation as a potential delivery method for vaccines. Vaccine, 1999;17:1796-1803.
16. LiCalsi C, Maniaci MJ, Christensen T, Phillips E, Ward GH, Witham C. A powder formulation of measles vaccine for aerosol delivery. Vaccine. 2001;19:2629-2636.
17. Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. 2001;51:81-96.
18. Maa YF, Ameri M, Shu C, Payne LG, Chen D. Influenza vaccine powder formulation development: spray-freeze-drying and stability evaluation. J Pharm Sci. 2004;93:1912-1923.
19. Maa YF, Shu C, Ameri M, et al. Optimization of an alum-adsorbed vaccine powder formulation for epidermal powder immunization. Pharm Res. 2003;20:969-977.
20. Treanor JJ, Kotloff K, Betts RF, et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine. 1999;18:899-906.
21. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998;338:1405-1412.
22. FluMist [package insert]. MedImmune Vaccines Inc., Gaithersburg, MD; 2003.
23. Soane RJ, Frier M, Perkins AC, Jones NS, Davis SS, Illum L. Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm. 1999;178:55-65.
24. Huang J, Garmise RJ, Crowder TM, et al. A novel dry powder influenza vaccine and intranasal delivery technology: induction of systemic and mucosal immune responses in rats. Vaccine. 2004;23:794-801.
25. Martin AN, Bustamante P. Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical Sciences. Philadelphia, PA: Lea & Febiger; 1993.
26. Carr RL Jr. Evaluating flow properties of solids. Chem Eng. 1965;72:163-168.
27. Carstensen JT. Pharmaceutical Principles of Solid Dosage Forms. Lancaster, PA: Technomic Pub; 1993.
28. Hickey AJ, Ganderton D. Pharmaceutical Process Engineering. New York, NY. Marcel Dekker; 2001.
29. Hinds WC. Aerosol Technology: Properties, Behavior and Measurement of Airborne Particles. New York, NY: J Wiley; 1999.
30. Cleland JL, Langer RSAmerican Chemical Society. Division of Biochemical Technology.Formulation and Delivery of Proteins and Peptides. Washington, DC: American Chemical Society; 1994.
31. Hageman M. Water sorption and solid state stability of proteins. In: Ahern TJ, Manning MC, eds. Stability of Protein Pharmaceuticals. New York, NY: Plenum Press; 1992;273-309.